Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 15, 2025
Principal Executive Offices: Bedminster, New Jersey
Trading Symbol: MTNB (NYSE American)
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a specific corporate transaction regarding equity securities.
Material Changes and Transactions
On August 15, 2025, the Company entered into Warrant Exchange Agreements with certain holders of warrants issued on April 5, 2024. Key details include:
- Warrants Exchanged: 466,666 warrants with an exercise price of $17.50 per share.
- Exchange Ratio: One share of Common Stock issued for each Warrant surrendered.
- Shares Issued: 466,666 shares of Common Stock (par value $0.0001).
- Outcome: The exchanged Warrants were cancelled, and no further shares are issuable pursuant to them.
- Regulatory Basis: The issuance relied on the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the unregistered sale of equity securities.
Investor Verification Checklist
- Verify the total number of outstanding warrants remaining after the cancellation of the 466,666 warrants.
- Confirm the impact of the 466,666 new shares on total diluted share count and potential dilution to existing shareholders.
- Review the full text of the Warrant Exchange Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Assess the Company's current cash position to determine if the exchange was a strategic move to avoid potential cash dilution from warrant exercises.